Shares of Cerulean Pharma Inc. (NASDAQ:CERU) saw an uptick in trading volume on Tuesday . 2,606,507 shares traded hands during mid-day trading, an increase of 1,115% from the previous session’s volume of 214,594 shares.The stock last traded at $2.65 and had previously closed at $2.28.

Several research firms have commented on CERU. Leerink Swann reiterated a “buy” rating on shares of Cerulean Pharma in a research report on Sunday, June 26th. Janney Montgomery Scott began coverage on Cerulean Pharma in a research report on Wednesday, June 1st. They issued a “buy” rating for the company. Canaccord Genuity reiterated a “buy” rating on shares of Cerulean Pharma in a research report on Tuesday, May 3rd. Finally, Wedbush reiterated an “outperform” rating and issued a $9.00 target price on shares of Cerulean Pharma in a research report on Tuesday, April 19th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $9.28.

The firm’s market capitalization is $80.99 million. The firm has a 50 day moving average price of $2.21 and a 200 day moving average price of $2.49.

Cerulean Pharma (NASDAQ:CERU) last posted its earnings results on Monday, May 2nd. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Analysts anticipate that Cerulean Pharma Inc. will post ($1.80) EPS for the current year.

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.